Viewing Study NCT00946257


Ignite Creation Date: 2025-12-24 @ 6:57 PM
Ignite Modification Date: 2026-01-22 @ 6:31 AM
Study NCT ID: NCT00946257
Status: COMPLETED
Last Update Posted: 2017-06-01
First Post: 2009-07-23
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Subcutaneous Administration of Otelixizumab to T1DM Patients
Sponsor: GlaxoSmithKline
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Diabetes Mellitus, Type 1 View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Type 1 Diabetes Mellitus View